Back to search

University of Patras

Ανάπτυξη λιποσωμικών μορφών μη-στεροειδών αντιφλεγμονωδών φαρμάκων (ΜΣΑΦ) για οφθαλμική χορήγηση

Abstract

dc:description

Non-steroidal anti-inflammatory drugs (NSAIDs) are cyclooxygenase (an enzyme that is involved in the metabolism of arachidonic acid into prostaglandins) inhibitors, and therefore, they inhibit the onset of inflammation. In ophthalmology, they are mainly used as eyedrops for topical administration, for therapy of inflammation, such as post-operative macular edema, without always providing the desired efficacy. Their intravitreal use has been tested in recent years for the cystic edema related with various types of macular degeneration, such as postoperative, diabetic, uveitis, with interesting results. Intravitreal (IVT) administration is known to provide significantly higher drug levels in the retina (compared to topical or systemic administration), while minimizing systemic adverse effects. The main drawback of these drugs is their short half-life in the vitreous cavity, which requires frequent injections to achieve the therapeutic effect. In order to develop a system for prolonged release of NSAIDs from the posterior segment of the eye, an in-situ liposome aggregation system (liposomal platform), was developed. For initial proof of the concept the fluorescent molecules of calcein and FITC-Dextran were used as model-drugs, after being encapsulate in liposomes. The system was studied in vitro and in vivo studies in order to confirm its functionality of. Subsequently, lornoxicam and flurbiprofen (FLB) liposomes were then prepared using a variety of liposome preparation techniques and optimized with the aim to achieve highest encapsulation efficiency and lowest particle size, in order to select the best drug to continue studies with. Actively loaded FLB Liposomes (with lipid composition of HPC/DPPG/Chol (9/1/10 mol: mol)), had the highest encapsulation yield and were thus selected. In vitro physicochemical characterization and drug release kinetics were subsequently evaluated. FLB solution, and plain liposomes were used as reference formulations.A second sustained release system was also developed; a thermosensitive hydrogel based on Pluronic F127 polymer, which incorporated FLB or FLB liposomes. In vitro release studies were conducted in order to investigate the optimal polymer concentration that would yield the slowest release rate. FL solution, plain liposomes and simple hydrogel were used as reference formulations. The optimal Pluronic F127 concentration was 18% w/v.In vitro studies of both hybrid liposomal systems, the liposomal platform and the liposomal hydrogel, confirmed that they should provide significant prolongation of the retention of the drug in the eye, in relation to the reference formulations. The liposomal platform released 20% of entrapped drug after 24 hours, while the liposomal hydrogel released 30% at the same time period. Both systems released measurable amounts of FLB for up to 120 h. Conclusively, two novel hybridic liposomal systems have that succeed to significantly extend the residence time of flurbiprofen (in vitro) and are suitable for intraocular administration, have been developed.

Degree

thesis:*
Grantor dc:publisher
University of Patras
Year dc:date
2017

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Pachis, Konstantinos
  • Παχής, Κωνσταντίνος

Subjects

dc:subject × 6

Rights

dc:rights
Statement dc:rights
  • BY
Language dc:language
gre

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/41732

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Pachis, Konstantinos; Παχής, Κωνσταντίνος. Ανάπτυξη λιποσωμικών μορφών μη-στεροειδών αντιφλεγμονωδών φαρμάκων (ΜΣΑΦ) για οφθαλμική χορήγηση. University of Patras, 2017. http://hdl.handle.net/10442/hedi/41732